Dividend

Totaal dividend boekjaar 2018: € 0,000*

Slot-dividend

voorgesteld bedrag
€ 0,000
datum aankondiging
mei 7, 2019
datum ex-dividend
datum betaling

Dividend historie

financiële events

Bedrijfsinformatie

Helaas hebben we deze informatie nog niet beschikbaar in het Nederlands. Nu wordt de Engelse versie getoond.

source: company website, January 2019

argenx is a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer. We are focused on developing product candidates with the potential to be either first-in-class against novel targets or best-in-class against known, but complex, targets in order to treat diseases with a significant unmet medical need. Our ability to execute on this focus is enabled by our suite of differentiated technologies. Our SIMPLE Antibody™ Platform, based on the powerful llama immune system, allows us to exploit novel and complex targets, and our three antibody engineering technologies are designed to enable us to expand the therapeutic index of our product candidates.  
argenx is listed on the Euronext Brussels exchange under the symbol ARGX.

Dividendbeleid

Helaas hebben we deze informatie nog niet beschikbaar in het Nederlands. Nu wordt de Engelse versie getoond.

Source: annual report 2017

We do not expect to pay cash dividends in the foreseeable future.